Since increased interleukin (IL)-6 has been associated with progression of androgen-dependent prostate cancer to androgen independence (20–26), we hypothesized that atorvastatin and celecoxib in combination would strongly inhibit the increased formation of IL-6 that occurs during the formation of androgen-independent LNCaP prostate tumors and that this inhibition would lead to the suppression of prostate cancer growth. The gene discussed is IL6; the disease is prostate neoplasm.